A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(29 sites)

China

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Beijing Cancer Hospital, Beijing, Beijing Municipality

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian